Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jose M. Marin Trigo (Zaragoza, Spain), Jose M. Marin Trigo, Maria Martinez, Pablo Cubero, Marta Forner, Marina Saetta, Manuel G. Cosio. Blood eosinophils and outcomes in COPD. Eur Respir J 2016; 48: Suppl. 60, 4624

Member's Comments

No comment yet.

Related content which might interest you: Exacerbations in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS, NHLBI) are associated with sputum eosinophilia but not blood eosinophilia Source: International Congress 2016 – What's new in biomarker analysis? Year: 2016 The relationship between blood neutrophils, blood eosinophils and exacerbations of COPD – Results from the TIE-study Source: International Congress 2016 – Systemic biomarkers Year: 2016 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 Assessment of malondialdehyde in the airways during treatment of COPD exacerbations Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 Relationship of blood eosinophil count to exacerbations in COPD Source: International Congress 2016 – Airway response to infection Year: 2016 Cells biomarkers of bronchial brush-biopsies at COPD exacerbation Source: Annual Congress 2013 –Research questions on how viruses affect the respiratory system Year: 2013 Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations Source: Annual Congress 2013 –Investigating COPD in longitudinal studies Year: 2013 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Monitoring catalase activity in COPD exacerbations Source: International Congress 2016 – Airway biomarkers Year: 2016 Can red blood cell morphology be an indicator for COPD exacerbations? Source: International Congress 2014 – Markers Year: 2014 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016 Can blood eosinophils predict sputum eosinophils in stable COPD? Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Inflammatory serum profiles are consistent across independent exacerbations in COPD patients with a history of frequent exacerbations Source: International Congress 2015 – COPD: interesting notes Year: 2015 Assessment of sputum prostaglandins and leukotrienes in COPD exacerbations Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Endothelial dysfunction and systemic inflammation in different COPD phenotypes Source: International Congress 2014 – COPD physiopathology Year: 2014 Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014